By Kevin Stawicki ( December 4, 2019, 1:43 PM EST) -- AstraZeneca has agreed to sell the rights to its antipsychotic Seroquel in the U.S. and Canada for $35 million, in a move that offloads the bipolar drug at the center of recent litigation accusing the pharmaceutical giant of running a pay-for-delay scheme to block generic versions....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.